View Item 

Show simple item record

Phase II evaluation of MGBG in non-small cell carcinoma of the lung
dc.contributor.authorVance, Ralph B.en_US
dc.contributor.authorKnight, William A.en_US
dc.contributor.authorChen, T. Timothyen_US
dc.contributor.authorCostanzi, John J.en_US
dc.contributor.authorLoBuglio, Albert F.en_US
dc.date.accessioned2006-09-11T15:42:17Z
dc.date.available2006-09-11T15:42:17Z
dc.date.issued1983-03en_US
dc.identifier.citationVance, Ralph B.; Knight, William A.; Chen, T. Timothy; Costanzi, John J.; LoBuglio, Albert F.; (1983). "Phase II evaluation of MGBG in non-small cell carcinoma of the lung." Investigational New Drugs 1(1): 89-93. <http://hdl.handle.net/2027.42/45128>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45128
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6678859&dopt=citationen_US
dc.description.abstractOne hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m 2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with squamous cell carcinoma. No responses were noted in 24 patients with large cell carcinoma. Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial antitumor activity for patients with non-small cell lung cancer.en_US
dc.format.extent300551 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherMartinus Nijhoff, The Hague/Kluwer Academic Publishers; Martinus Nijhoff Publishers ; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherMethyl-glyoxal-Bis-guanylhydrazoneen_US
dc.subject.otherMGBGen_US
dc.subject.otherNon-small Cell Carcinoma of the Lungen_US
dc.titlePhase II evaluation of MGBG in non-small cell carcinoma of the lungen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Michigan, USAen_US
dc.contributor.affiliationotherUniversity of Mississippi School of Medicine, Mississippi, USAen_US
dc.contributor.affiliationotherUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Biostatistical Center, USAen_US
dc.contributor.affiliationotherUniversity of Texas Medical Branch at Galveston, Galveston, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid6678859en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45128/1/10637_2004_Article_BF00180196.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00180196en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00180196.pdf
Size:
293.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.